Real ‐world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post‐marketing study

ConclusionsMirabegron was well tolerated in real‐world Japanese patients with overactive bladder and coexisting cardiovascular disease. No unexpected cardiovascular safety concerns were observed.

Source: International Journal of Urology - September 12, 2016 Category: Urology & Nephrology Authors: Takao Katoh, Kana Kuwamoto, Daisuke Kato, Kentarou Kuroishi Tags: Original Article Source Type: research